A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
Study Number: J2J-MC-JZLH/EMBER 4
Study Summary:
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Status: Open
Peoria, Bloomington, Galesburg, Pekin, Washington, Ottawa, Peru
Study Coordinator(s)
- Navigator Angie, 309-243-3613, aearles@illinoiscancercare.com
- Kelsey, 309-243-3618 kfay@illinoiscancercare.com
